Overview

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Keryx Biopharmaceuticals
Collaborator:
Collaborative Study Group (CSG)
Treatments:
Citric Acid
Ferric Compounds